FUS Protein-Targeting Therapy for ALS/FTD

Overview

This therapeutic approach targets FUS (Fused in Sarcoma) proteinopathy, a core pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS is an RNA-binding protein that normally resides in the nucleus but mislocalizes to cytoplasmic inclusions in a subset of ALS and FTD cases. This approach combines RNA-targeting strategies with proteostasis enhancement to reduce toxic FUS aggregates and restore nuclear function.

Mechanism of Action

Pathological Context

FUS is a 526-amino acid RNA-binding protein involved in RNA splicing, transport, and DNA repair. In ~5-10% of ALS cases and ~10% of FTD cases, FUS accumulates in cytoplasmic inclusions alongside [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology[@kwiatkowski2009][@vance2009]. Mutations in the FUS gene (ALS6 locus) cause familial ALS, demonstrating that FUS dysfunction is disease-causing.

Key pathological features:

• Nuclear export dysregulation: FUS mutations impair nuclear localization signals (NLS), leading to cytoplasmic accumulation[@dormann2010]
• Liquid-liquid phase separation failure: Disease mutations disrupt FUS liquid-liquid phase separation (LLPS), promoting solid aggregate formation[@sharma2016][@murray2018]
• RNA metabolism disruption: Cytoplasmic FUS sequesters RNA and mRNA transport proteins
• Stress granule persistence: FUS-positive stress granules persist instead of dissolving, becoming toxic aggregates[@tibshirani2016][@monahan2016]

Therapeutic Strategy

...

Overview

This therapeutic approach targets FUS (Fused in Sarcoma) proteinopathy, a core pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS is an RNA-binding protein that normally resides in the nucleus but mislocalizes to cytoplasmic inclusions in a subset of ALS and FTD cases. This approach combines RNA-targeting strategies with proteostasis enhancement to reduce toxic FUS aggregates and restore nuclear function.

Mechanism of Action

Pathological Context

FUS is a 526-amino acid RNA-binding protein involved in RNA splicing, transport, and DNA repair. In ~5-10% of ALS cases and ~10% of FTD cases, FUS accumulates in cytoplasmic inclusions alongside [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology[@kwiatkowski2009][@vance2009]. Mutations in the FUS gene (ALS6 locus) cause familial ALS, demonstrating that FUS dysfunction is disease-causing.

Key pathological features:

• Nuclear export dysregulation: FUS mutations impair nuclear localization signals (NLS), leading to cytoplasmic accumulation[@dormann2010]
• Liquid-liquid phase separation failure: Disease mutations disrupt FUS liquid-liquid phase separation (LLPS), promoting solid aggregate formation[@sharma2016][@murray2018]
• RNA metabolism disruption: Cytoplasmic FUS sequesters RNA and mRNA transport proteins
• Stress granule persistence: FUS-positive stress granules persist instead of dissolving, becoming toxic aggregates[@tibshirani2016][@monahan2016]

Therapeutic Strategy

Primary Mechanism: Reduce FUS expression using RNA-targeting approaches (ASO, RNAi) or enhance FUS clearance through [autophagy](/entities/autophagy) enhancement.

Secondary Mechanism: Target stress granule dynamics using small molecules that promote granule dissolution without blocking protective stress response.

Tertiary Mechanism: Nuclear import enhancement using nuclear localization signal (NLS) peptide conjugates or small molecule nuclear import enhancers.

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9 | First-in-class mechanism targeting FUS proteinopathy distinct from TDP-43 approaches |
| Mechanistic Rationale | 8 | Strong genetic evidence (FUS mutations cause ALS6), pathology confirmed in sporadic cases |
| Addresses Root Cause | 8 | Targets protein aggregation at source rather than downstream effects |
| Delivery Feasibility | 6 | CNS delivery achievable via intrathecal ASO (proven in other ALS programs) |
| Safety Plausibility | 7 | Allele-specific targeting possible for mutant FUS sparing wild-type function |
| Combinability | 8 | Synergistic with TDP-43 targeted therapies, autophagy enhancers |
| Biomarker Availability | 7 | CSF FUS levels, pNfH as neurodegeneration marker, FUS PET ligands in development |
| De-risking Path | 7 | iPSC-derived [neurons](/entities/neurons) from FUS-ALS patients, FUS transgenic mouse models exist |
| Multi-disease Potential | 8 | ALS, FTD, and rare FUS-linked encephalopathies |
| Patient Impact | 8 | Addresses rapidly progressive motor neuron disease with high unmet need |

Total Score: 76/100

Preclinical Evidence

Genetic Evidence

• FUS mutations cause ALS6 (autosomal dominant): P525L, R521C, R521H, R522G[@kwiatkowski2009][@vance2009]
• FUS inclusions found in 5-10% of sporadic ALS cases
• FUS-FTD represents ~10% of all FTD cases

Preclinical Models

• FUS-ALS iPSC models: Motor neurons show cytoplasmic FUS mislocalization, stress granule persistence, and axonal transport defects[@tibshirani2016]
• Transgenic mice: FUS P525L knock-in mice develop ALS phenotype with FUS inclusions[@tibshirani2016]
• Cell models: FUS LLPS mutants show accelerated aggregation and reduced dissolution[@sharma2016][@murray2018]

Small Molecule Screening

• Stress granule modulators: Several compounds identified that promote stress granule dissolution
• Autophagy enhancers: Rapamycin, [TFEB](/entities/tfeb) activators enhance FUS aggregate clearance in cellular models

Development Pathway

Phase 1: Target Validation (Months 1-12)

• Validate FUS as therapeutic target in patient-derived iPSC neurons
• Confirm allele-specific ASO approach feasibility
• Develop CSF biomarker for target engagement
• Go/No-Go: Demonstrate >50% FUS reduction without toxicity

Phase 2: Preclinical Development (Months 10-24)

• Lead ASO optimization for CNS delivery
• GLP toxicology in non-human primates
• Biomarker assay validation
• IND-enabling studies
• Go/No-Go: Positive GLP toxicology, biomarker assay qualified

Phase 3: Clinical Development (Months 24-48)

• Phase 1 safety in healthy volunteers (if applicable)
• Phase 2 dose-finding in FUS-ALS/FTD patients
• Biomarker validation for patient enrichment
• Go/No-Go: Clear target engagement signal, acceptable safety

Phase 3b: Pivotal (Months 48-72)

• Registrational trial in FUS-ALS
• Parallel FTD cohort expansion
• Accelerated approval based on biomarker endpoints

Implementation Roadmap

| Phase | Timeline | Cost | Key Milestones |
|-------|----------|------|----------------|
| Phase 1 | 12 months | $3-5M | Target validation, lead identification |
| Phase 2 | 14 months | $8-15M | IND-enabling studies, GLP toxicology |
| Phase 3 | 24 months | $25-40M | Clinical trials, registration |
| Total | 50 months | $36-60M | |

Academic Centers

• University of Michigan (FUS-ALS expertise, Dr. Eva Feldman)
• University of Massachusetts (ALS research, Dr. Robert Brown)
• Stanford University (FTD research, Dr. Michael Greicius)
• University College London (Motor Neuron Disease Centre)

Company Partnership Opportunities

Ionis Pharmaceuticals — ASO platform, existing ALS programs (tofersen for SOD1)

Biogen — CNS delivery expertise, ALS franchise

Ribon Therapeutics — Stress granule biology expertise

Prothelia — Rare disease focus, FUS biology

Actionable Next Steps

Lab Experiments

Test allele-specific ASOs in FUS-ALS patient iPSC-derived motor neurons

Screen stress granule modulators for FUS clearance efficacy

Validate autophagy enhancement strategies (TFEB activation, rapamycin)

Develop FUS PET ligand for patient stratification

Clinical Protocol Design

Patient Population: FUS mutation carriers, sporadic ALS with FUS pathology

Enrichment Strategy: CSF FUS levels, genetic testing for FUS mutations

Dose-Finding Design: Bayesian adaptive design with biomarker endpoints

Endpoints: ALSFRS-R, CSF biomarkers, survival

Company Partnerships

Ionis: Leverage ASO platform, discuss FUS program option

Biogen: Explore partnership for clinical development

Roche: Discuss potential collaboration on FTD indication

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Related Pages

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [FUS Gene](/mechanisms/dopaminergic-neuron-vulnerability)
• [TDP](/mechanisms/tdp-43-proteinopathy)
• [Stress Granules](/cell-types/stress-granules-rnp)
• [Molecular Glue for TDP](/ideas/payload-molecular-glue-tdp43)
• [C9orf72 RNA](/ideas/c9orf72-rna-targeting-dpr-reduction)

Cross-Links

• [ALS Treatment Pipeline](/mechanisms/dopaminergic-neuron-vulnerability)
• [RNA](/therapeutics/rna-targeting-therapies-neurodegeneration)
• [Proteostasis Enhancement](/mechanisms/dopaminergic-neuron-vulnerability)

References

[Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al, Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis (2009)](https://pubmed.ncbi.nlm.nih.gov/19350693/)

[Vance C, Rogelj B, Hortobágyi T, et al, Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6 (2009)](https://pubmed.ncbi.nlm.nih.gov/19350694/)

[Dormann D, Rodde R, Edbauer D, et al, ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import (2010)](https://pubmed.ncbi.nlm.nih.gov/20168091/)

[Sharma A, Lyakhovetsky V, Ok A, et al, ALS-associated FUS mutations lead to mechanical cracking of RNA stress granules (2016)](https://pubmed.ncbi.nlm.nih.gov/27845388/)

[Murray DT, Kato M, Lin Y, et al, Structure of FUS protein fibrils and its relevance to self-assembly and phase separation (2018)](https://pubmed.ncbi.nlm.nih.gov/29420199/)

[Tibshirani M, Tradewell ML, Mattedi K, et al, Cytoplasmic accumulation of FUS in motor neurons is sufficient to cause ALS-like phenotypes in mice (2016)](https://pubmed.ncbi.nlm.nih.gov/26555377/)

[Monahan Z, Shewmaker F, Pandey UB, Stress granules in ALS and FTD: emerging mechanistic insights (2016)](https://pubmed.ncbi.nlm.nih.gov/27343457/)

[Japtap J, Lanson EA, Jin IW, et al, FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage (2017)](https://pubmed.ncbi.nlm.nih.gov/28972080/)

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving FUS Protein-Targeting Therapy for ALS/FTD discovered through SciDEX knowledge graph analysis: